Chemotherapy versus best supportive care in advanced lung cancer and idiopathic interstitial pneumonias: A retrospective multi-centre cohort study

Miyamoto, Atsushi; Michimae, Hirofumi; Nakahara, Yasuharu; Akagawa, Shinobu; Nakagawa, Kazuhiko; Minegishi, Yuji; Ogura, Takashi; Hontsu, Shigeto; Date, Hiroshi; Takahashi, Kazuhisa; Homma, Sakae; Kishi, Kazuma

doi:10.1016/j.resinv.2022.10.009

Cited by 4 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been several studies to evaluate risk factors except mGAP index score for the development of AE-ILD caused by cytotoxic chemotherapy in patients with LC-ILD. Putative predictive factors for chemotherapy-related AE-ILD were reported to be : performance status ≥ 2 (72), usual interstitial pneumonia (UIP) patterns in high-resolution computed tomography (73,74), a pathologic NSCLC type (75), impaired pulmonary function (73,75), and elevated serum KL-6 and surfactant proteins D level (72), although these factors remain inconclusive due to insufficient evidence. A subgroup analysis of a recent meta-analysis showed the difference in 1-year survival rate between studies with better lung function and those with poorer lung function was significant (56.0% vs. 29.0%), suggesting the usefulness of evaluating lung function in chemotherapy for patients with Table 2.…”

Section: The Incidence and Risk Factors Of Ae-ild In Lc-ild Induced B...mentioning

confidence: 99%

“…More recently, Miyamoto et al performed a retrospective multi-center cohort study to investigate whether chemotherapy improves OS and influences the risk of AE in LC-IIPs compared to BSC. Their findings suggest that chemotherapy as initial treatment for LC-IIPs improves OS (hazard ratio [HR] : 0.629, 95% CI : 0.506-0.783) irrespective of LC histology ; however, it was significantly associated with AE-ILD (OR : 1.787, 95% CI : 1.026-3.113) compared to BSC (72). Although there is no drug with adequately established safety for the treatment of LC-ILD at present, the aforementioned findings suggest that traditional chemotherapy still plays a critical role in the treatment of this patient population.…”

Section: The Effect Of First-line Chemotherapy For Nsclc-ildmentioning

confidence: 99%

See 1 more Smart Citation

Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : A literature review and future perspectives

Hanibuchi,

Ogino,

Sato

et al. 2024

J. Med. Invest.

View full text Add to dashboard Cite

Patients with interstitial lung disease (ILD), especially those with idiopathic pulmonary fibrosis, are at increased risk of developing lung cancer (LC). Pharmacotherapy for advanced LC has dramatically progressed in recent years ; however, management of LC with pre-existing ILD (LC-ILD) is challenging due to serious concerns about the risk of acute exacerbation of ILD (AE-ILD). As patients with LC-ILD have been excluded from most prospective clinical trials of advanced LC, optimal pharmacotherapy remains to be elucidated. Although the antitumor activity of first-line platinum-based cytotoxic chemotherapy appears to be similar in advanced LC patients with or without ILD, its impact on the survival of patients with LC-ILD is limited. Immune checkpoint inhibitors may hold promise for long-term survival, but many challenges remain, including safety and appropriate patient selection. Further understanding the predictive factors for AE-ILD after receiving pharmacotherapy in LC-ILD may lead to appropriate patient selection and lower treatment risk. The aim of this review was to summarize the current evidence related to pharmacotherapy for advanced LC-ILD and discuss emerging areas of research.

show abstract

Section: The Incidence and Risk Factors Of Ae-ild In Lc-ild Induced B...mentioning

confidence: 99%

Section: The Effect Of First-line Chemotherapy For Nsclc-ildmentioning

confidence: 99%

Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : A literature review and future perspectives

Hanibuchi,

Ogino,

Sato

et al. 2024

J. Med. Invest.

View full text Add to dashboard Cite

show abstract

Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy

Miyamoto,

Michimae,

Nakahara

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Effective treatment for advanced lung cancer and idiopathic interstitial pneumonia (IIP) remains an unmet medical need. The relationship between chemotherapy’s effectiveness in advanced lung cancer and the risk of acute exacerbation of IIP is poorly investigated. There is limited evidence that patients who experience an acute exacerbation of IIPs during cytotoxic chemotherapy have poorer outcomes than those who do not. Among 1004 patients with advanced lung cancer and IIPs enrolled in our published multi-centre retrospective study from 110 Japanese institutions, 708 patients (male: female, 645:63; mean age, 70.4) received first-line chemotherapy. The occurrence of chemotherapy-triggered acute exacerbations of IIPs and overall survival (OS) were analysed. The OS between groups of patients with and without the occurrence of acute exacerbation was compared at four landmark time points (30, 60, 90, and 120 days), starting from the first-line chemotherapy, using the landmark method. The incidence of acute exacerbation in patients who received first-line chemotherapy with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) was more frequent in NSCLC patients than in SCLC (4.2% vs 12.6%; odds ratio [OR]: 3.316; 95% confidence interval [CI] 1.25–8.8). Median survival time was 9.9 months (95% CI 9.2–10.7). Patients who experienced acute exacerbation had significant worse survival outcomes than those who did not at various time points (30 days, hazard ratio [HR]: 5.191, 95% CI 2.889–9.328; 60 days, HR: 2.351, 95% CI 1.104–5.009; 90 days, HR: 2.416, 95% CI 1.232–4.739; and 120 days, HR: 2.521, 95% CI 1.357–4.681). Acute exacerbation during first-line chemotherapy can predict poor survival.Trial Registration number: UMIN000018227.

show abstract

Bayesian parametric estimation based on left-truncated competing risks data under bivariate Clayton copula models

Michimae,

Emura,

Miyamoto

et al. 2024

Journal of Applied Statistics

View full text Add to dashboard Cite

Chemotherapy versus best supportive care in advanced lung cancer and idiopathic interstitial pneumonias: A retrospective multi-centre cohort study

Cited by 4 publications

References 39 publications

Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : A literature review and future perspectives

Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : A literature review and future perspectives

Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy

Bayesian parametric estimation based on left-truncated competing risks data under bivariate Clayton copula models

Contact Info

Product

Resources

About